AtriCure price target raised to $19 on acquisition at Canaccord Canaccord raised AtriCure's price target to $19 from $16 based on the strategic acquisition of privately held Estech. The analyst said Estech has a strong cache of IP in the ablation space with over 200 patents. Shares are Buy rated.
News For ATRC From The Last 14 Days
Check below for free stories on ATRC the last two weeks.